KYTX Stock Analysis: Buy, Sell, or Hold?
KYTX - Kyverna Therapeutics, Inc. Common Stock
$8.77
0.14 (1.62%)
▲
5d:
+11.44%
30d:
+9.35%
90d:
-6.2%
BUY
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
KYTX is down 11.3% this week, but smart money is accumulating calls. Top strike: $10 2026-06-18 with 1,211 OI. Call ratio: 100% View Scanner →
Strength: 10.0/10
Get Alerted When KYTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: KYTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: KYTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: KYTX is currently trading at $8.77, which is considered extended relative to its 30-day fair value range of $7.88 to $8.81.
Technical Outlook: Technically, KYTX is in a uptrend. Immediate support is located at $7.34, while resistance sits at $9.30.
Market Sentiment: KYTX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $29.60 (+237.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, KYTX is in a uptrend. Immediate support is located at $7.34, while resistance sits at $9.30.
Market Sentiment: KYTX has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $29.60 (+237.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$7.88 -
$8.81
Company Quality Score
64/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 237.5% below Wall St target ($29.60)
Fair Price Analysis
30-Day Fair Range
$7.88 -
$8.81
Current vs Fair Value
EXTENDED
Support & Resistance Levels
Support Level
$7.35
Resistance Level
$9.30
Current Trend
Uptrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.03
Wall Street Target
$29.60
(+237.5%)
Share & Embed Analysis
Last updated: April 02, 2026 6:12 AM ET
Data refreshes hourly during market hours. Next update: 7:12 AM
Data refreshes hourly during market hours. Next update: 7:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KYTX showing a specific setup today?
Insider Activity (6 Months)
2
Buys
1
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Beth C Seidenberg
BUY
133333 shares
2025-12-18
Biopartners Opportuni We…
BUY
133333 shares
2025-12-18
Karen Marie Walker
SELL
23998 shares
2025-12-15
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 63 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 65 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 62 BUY |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$547 | 52 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$119 | 59 HOLD |
